Evidence map›Paper›PMID 33708852›Full record

ArticleAnnals of translational medicine2021

Jan Trøst Jørgensen, Jens Mollerup, Hui Yang, Ning Go, Karsten Bork Nielsen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Jan Trøst JørgensenCompanion Diagnostics, Dx-Rx Institute, Fredensborg, Denmark.
Jens MollerupPathology Division, Agilent Technologies, Glostrup, Denmark.
Hui YangMedical Sciences, Amgen Inc., Thousand Oaks, USA.
Ning GoMedical Sciences, Amgen Inc., Thousand Oaks, USA.
Karsten Bork NielsenBork Enterprises, Virum, Denmark.
Amgen (United States) · USAgilent Technologies (Denmark) · DKDXC Technology (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsTissue specimens from 1,580 patients were analyzed using a novel fluorescence in situ hybridization (FISH) assay employing a

resultsThe prevalence of

conclusionsThe screening data from this cross-sectional study showed that

Indexed as

amplificationdeletionfluorescence in situ hybridization (FISH)gastric cancerMesenchymal epithelial transition factor gene (MET)

Identifiers

PMID33708852
PMCPMC7940901
OpenAlexW3123827448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.